For years, American travellers have returned from Europe, Japan and South Korea asking the same question:
Why do their sunscreens feel so much better?
Overseas products often spread more easily, leave less white residue and provide strong UVA protection in lightweight fluids, gels and essences. American sunscreens, by comparison, have frequently depended on an older and narrower range of ultraviolet filters.
The difference was not simply that foreign skincare companies possessed better formulation technology.
It was largely regulatory.
In the United States, sunscreen is regulated as an over-the-counter drug. In the European Union and many Asian markets, it is regulated primarily as a cosmetic product. That gives the FDA a more demanding approval pathway---but it also left American formulators unable to use several filters that had been sold internationally for decades.
That began to change on June 9, 2026, when the FDA added bemotrizinol, commonly sold under the trade name Tinosorb S, to the US sunscreen monograph.
It was the first new sunscreen active ingredient added to the American monograph since the late 1990s.
The decision is historic.
It does not eliminate the gap.
*This is one signal from the Consensys Innovation Signals Engine, which continuously scans a library of more than one million products worldwide for emerging shifts in formulation, positioning and consumer demand.*
**Tinosorb S finally crossed the border**
Bemotrizinol is a highly photostable organic UV filter that protects across both UVA and UVB wavelengths.
It can also help stabilise other filters in a formula, allowing manufacturers to build broad-spectrum products with strong protection and more elegant textures.
The ingredient has been used internationally since around 1999, including in sunscreens sold across Europe and Asia. In December 2025, the FDA proposed adding it after reviewing evidence showing broad-spectrum performance, low skin absorption and infrequent irritation.
Six months later, the agency issued its final order.
Innovation Type: Next-Generation Broad-Spectrum UV Filter
Ingredient: Bemotrizinol
Trade Name: Tinosorb S
US Regulatory Status: Permitted from June 2026
International Use: More than two decades
The approval gives American brands a new formulation tool. But the first products still need to be developed, stability-tested, manufactured and launched.
US consumers will not immediately find every European or Korean sunscreen experience replicated on domestic shelves.
**The American filter library remains much smaller**
Before the bemotrizinol decision, the US monograph listed 16 sunscreen active ingredients. Several are now rarely used, while only zinc oxide and titanium dioxide were proposed by the FDA as having sufficient evidence to be considered generally recognised as safe and effective without additional data.
With bemotrizinol, the nominal list rises to 17.
Europe permits roughly 30 or more filters, depending on how ingredients and current restrictions are counted. Dermatology reviews have consistently found that European formulators have access to substantially more modern UVA and broad-spectrum options than US companies.
That broader toolkit includes filters such as:
- Bisoctrizole --- Tinosorb M
- Drometrizole trisiloxane --- Mexoryl XL
- Diethylamino hydroxybenzoyl hexyl benzoate --- Uvinul A Plus
- Ethylhexyl triazone --- Uvinul T 150
- Iscotrizinol --- Uvasorb HEB
These ingredients differ in the wavelengths they absorb, their solubility, photostability and compatibility with other components.
Having more approved filters gives formulators more ways to balance:
- UVA protection
- UVB protection
- High SPF
- Photostability
- Skin feel
- Transparency
- Water resistance
- Eye-area comfort
- Suitability for different skin tones
Signal: Regulatory Access Shapes Product Experience
**High SPF does not automatically mean strong UVA protection**
SPF primarily measures protection against sunburn-producing UVB radiation.
UVA penetrates more deeply into the skin and contributes to photoaging, pigmentation and skin-cancer risk. A product can achieve a high SPF while offering less impressive protection across the longer UVA wavelengths.
US products labelled Broad Spectrum must pass the FDA's critical-wavelength test. But international systems may communicate UVA performance using additional measures such as:
- UVA-PF
- PPD
- PA ratings
- The European requirement that UVA protection reach at least one-third of labelled SPF
The result is not that every foreign sunscreen is automatically superior.
It is that foreign formulators often have more ingredients available when trying to achieve high UVA protection without creating a heavy or unpleasant product.
Performance Territory: Long-Wave UVA Protection
**Better filters can create better textures**
The regulatory debate can sound abstract until it is translated into the way sunscreen feels.
Formulators working with a limited filter palette may need to use higher concentrations or more complicated combinations to achieve a target SPF and broad-spectrum claim.
That can contribute to:
- Greasiness
- Pilling
- Eye irritation
- White cast
- Heavy film formation
- Instability
- Difficulty layering beneath makeup
Newer filters do not automatically solve every formulation problem. The inactive ingredients, emulsion system, powders and manufacturing process remain critical.
But a wider selection gives product developers greater flexibility.
This helps explain the popularity of products from brands such as:
- Beauty of Joseon
- Round Lab
- Isntree
- La Roche-Posay
- Eucerin
- Bioderma
- Anessa
- Biore UV
Consumers are not only buying higher protection.
They are buying sunscreens that feel easier to use every day.
Innovation Type: Sensory Compliance
A sunscreen provides little public-health value if its texture discourages people from applying enough of it.
**The US did approve Mexoryl SX---but only through a narrower route**
The original research row states that Mexoryl SX remains FDA-unapproved.
That is not fully accurate.
Ecamsule, marketed as Mexoryl SX, was approved by the FDA in 2006 in specific L'Oréal sunscreen formulations through the New Drug Application pathway. FDA documents show approvals for several ecamsule-containing products.
But ecamsule was not broadly added to the sunscreen monograph.
That meant other manufacturers could not simply formulate with it under the same general OTC framework. They would need an approved application or another lawful pathway tied to a specific product.
This distinction illustrates the regulatory problem:
A filter can be technically approved in one product without becoming widely available to the whole market.
Mexoryl XL, a different L'Oréal filter, remains unavailable as a general US sunscreen active.
**Why did the FDA take so long?**
The FDA's caution is not irrational.
Sunscreen is applied repeatedly, often over large areas of skin and across a lifetime. The agency wants evidence addressing:
- Systemic absorption
- Long-term toxicity
- Reproductive effects
- Carcinogenicity
- Skin irritation
- Allergic reactions
- Paediatric use
- Maximum-use exposure
FDA studies found that several established sunscreen ingredients can be absorbed into the bloodstream above thresholds that trigger further safety testing. The agency stressed that detection does not prove harm and continued to recommend sunscreen use.
The problem was not simply that the FDA asked for evidence.
It was that the older approval framework was slow, expensive and poorly suited to ingredients already used extensively overseas.
Congress passed the Sunscreen Innovation Act in 2014 to create a clearer review route. Further OTC-drug reforms followed through the CARES Act in 2020. Yet no new filter entered the general sunscreen monograph until 2026.
Even the FDA acknowledged the delay. When proposing bemotrizinol, Commissioner Marty Makary said the agency had historically moved too slowly and left Americans with fewer choices than consumers abroad.
Risk Signal: Regulatory Caution Becoming Innovation Delay
**Overseas sunscreen became a parallel market**
The filter gap helped create a thriving American market for imported sunscreens.
Consumers buy Korean, Japanese, European and Australian products through:
- Specialist beauty retailers
- International e-commerce sites
- Marketplace sellers
- Travel purchases
- Cross-border social-commerce channels
This market grew through reviews describing foreign products as:
- More wearable
- Less greasy
- More transparent
- Better beneath makeup
- More suitable for darker skin tones
- Stronger in UVA protection
But imported products introduce complications.
A sunscreen legally sold as a cosmetic in another country may not comply with US drug-labelling and monograph requirements. Some brands therefore sell a different formula in the United States from the version available in their home market.
Consumers may also encounter:
- Counterfeit products
- Unauthorised sellers
- Poor storage conditions
- Confusing date labels
- Reformulated versions
- Products not tested under US methods
Market Signal: Regulation-Driven Grey Import Demand
**American sunscreen was not universally "bad"**
The title captures a real frustration but requires qualification.
US sunscreens can provide effective protection when they meet broad-spectrum requirements and are applied correctly. Mineral filters such as zinc oxide can offer strong UVA and UVB coverage, while properly formulated avobenzone systems can perform well.
American brands have also innovated in:
- Tinted mineral sunscreens
- Sheer zinc technologies
- Silicone gels
- Brush-on formats
- Sunscreen sticks
- Makeup-sunscreen hybrids
- Sport and water-resistant products
The core disadvantage was not an absence of capable products.
It was reduced formulation choice.
A smaller filter library made it harder to produce the full range of high-protection, elegant products available elsewhere.
**Tinosorb S could reshape several product territories**
Bemotrizinol's arrival gives US brands new opportunities in:
### High-UVA facial sunscreen
Its broad-spectrum coverage could support stronger daily anti-photoaging propositions.
### Sunscreen for darker skin tones
Organic filters can help brands reduce dependence on high mineral-filter loads that may leave a visible cast.
### Lightweight high-SPF products
Photostability and compatibility with other filters may support thinner fluids, gels and essences.
### Sensitive-skin formulations
The FDA's review found low absorption and infrequent irritation, although the full formula will determine tolerability.
### Hybrid skincare
Brands can combine sun protection with moisturising, pigmentation and anti-aging positioning in more cosmetically elegant formats.
Innovation Platform: US Next-Generation Sunscreen Reformulation
The ingredient may be especially valuable to L'Oréal, Beiersdorf, Johnson & Johnson/Kenvue, Edgewell, Supergoop, EltaMD and other companies competing in premium facial sun care.
**One approval does not modernise an entire category**
Bemotrizinol is a breakthrough, but it also highlights the scale of the backlog.
The United States still lacks monograph-wide access to several filters used routinely abroad. Each will require a sponsor willing to finance and submit the evidence needed for FDA review.
The 2026 approval proves the updated system can work.
The next test is whether it can work repeatedly.
Brands and ingredient suppliers will watch for progress on:
- Bisoctrizole / Tinosorb M
- Drometrizole trisiloxane / Mexoryl XL
- Uvinul A Plus
- Uvinul T 150
- Other modern UVA and UVB filters
Without further submissions and approvals, bemotrizinol risks becoming a single exception rather than the beginning of full reform.
**The sunscreen gap is finally narrowing**
For more than 25 years, American consumers watched other markets turn sunscreen into a sophisticated daily-skincare category while US formulators worked with a comparatively limited set of actives.
On June 9, 2026, that changed.
The first new monograph filter in decades does not instantly make American sunscreen equivalent to the best products sold internationally.
But it removes the argument that regulatory modernisation is impossible.
The next generation of US sunscreens will reveal whether brands use Tinosorb S merely to create more SPF products---or to build sunscreens people genuinely want to apply every day.
The real test of innovation is not the number of filters approved.
It is whether better regulation produces better protection in the hands of consumers.